Phase 1b of the OCARINA I Trial Reveals the Ideal Dosage for Subcutaneous Ocrelizumab.

Published Date: 15 Oct 2023

The 920 mg subcutaneous dose of ocrelizumab was well tolerated in patients with relapsing or primary progressive multiple sclerosis, with exposure similar to the FDA-approved intravenous dose, according to results from the OCARINA I study that were presented at the MSMilan 2023 meeting.

Read Full News

Latest News

Primary Care Making More Mental Health Diagnoses for Kids

Pediatric mental health visits in primary care surged over a 9-year period.

Electroacupuncture Promising for Cognitive Improvement in AD

Electroacupuncture was associated with long-term efficacy in improving cognitive function compared to sham treatment in patients with Alzheimer’s disease, a new trial shows.

Undiagnosed Dementia Tied to Increased Mortality Risk

Undiagnosed dementia is highly prevalent in the US and Brazil and is linked to increased 4-year mortality in both countries, a large cohort study shows.

Coffee Linked to Better Cognition in Patients With PD

Coffee consumption is associated with improved executive function in patients with early Parkinson’s disease, while smoking has no impact, a new study suggests.

How One Psilocybin Trip May Reshape the Brain

New research suggests a single high dose of psilocybin alters neural activity and may trigger lasting structural brain changes tied to improved well-being.

Brain Cooling Boosts LVO Recovery After Thrombectomy

Targeted intra-arterial cooling delivered during clot retrieval significantly increases functional independence after large-vessel ischemic stroke, with no added risk.

Todays Updates

EMA Backs Breast Cancer SERD After FDA No Vote

The recommendation follows phase 3 data showing longer progression-free survival when patients switched to camizestrant plus a CDK4/6 inhibitor.

Datopotamab Deruxtecan Earns New Breast Cancer Indication

The antibody drug conjugate was approved by the FDA for certain patients with triple-negative breast cancer.

Todays Updates

EMA Backs Breast Cancer SERD After FDA No Vote

The recommendation follows phase 3 data showing longer progression-free survival when patients switched to camizestrant plus a CDK4/6 inhibitor.

Datopotamab Deruxtecan Earns New Breast Cancer Indication

The antibody drug conjugate was approved by the FDA for certain patients with triple-negative breast cancer.

Latest News

Pediatric mental health visits in primary care surged over a 9-year period.

Electroacupuncture was associated with long-term efficacy in improving cognitive function compared to sham treatment in patients with Alzheimer’s disease, a new trial shows.

Undiagnosed dementia is highly prevalent in the US and Brazil and is linked to increased 4-year mortality in both countries, a large cohort study shows.

Coffee consumption is associated with improved executive function in patients with early Parkinson’s disease, while smoking has no impact, a new study suggests.

New research suggests a single high dose of psilocybin alters neural activity and may trigger lasting structural brain changes tied to improved well-being.

Targeted intra-arterial cooling delivered during clot retrieval significantly increases functional independence after large-vessel ischemic stroke, with no added risk.

News All Time

CTAD: Clinical Trials on Alzheimer's Disease Conference

The New Standard in Multiple Sclerosis: Integrating Evolving Treatment Evidence and Biomarkers to Target Progression

The New Standard in Multiple Sclerosis: Integrating Evolving Treatment Evidence and Biomarkers to Target Progression

Decoding Multifocal Motor Neuropathy: A Practical Guide to Diagnosis, Pathogenesis, and Emerging Innovations in Treatment

Decoding Multifocal Motor Neuropathy: A Practical Guide to Diagnosis, Pathogenesis, and Emerging Innovations in Treatment

AAN: American Academy of Neurology

ISC: International Stroke Conference

CTAD Video Pearls: Video Pearls from the Clinical Trials on Alzheimer's Disease Conference

AES: American Epilepsy Society

Rat Lungworm Is Now in My State. Is It in Yours Too?

The global, brain-invading parasite continues to spread

Severe Malaria in Kids Linked to Certain Cognitive, Academic Deficits Years Later

Impairment persisted after episodes of cerebral malaria or severe malarial anemia

Novel Agent Reduces Seizures in Treatment-Resistant Epilepsy

Adjunctive azetukalner cut monthly focal onset seizure frequency by 53% in phase III study

Suppressing a Sneeze May Have Led to Cerebrospinal Fluid Leak

While normally harmless, holding in a sneeze may in rare cases cause serious problems

First Clinical Trial in MOGAD Meets Primary Endpoint

Satralizumab cuts relapse risk in myelin oligodendrocyte glycoprotein antibody-associated disease

Cemdisiran siRNA Therapy Demonstrates Efficacy in Myasthenia Gravis

Investigational treatment improves outcomes without complete complement blockade

Stiff Person Syndrome Patients Regain Mobility After Single-Dose Cell Therapy

CAR-T therapy shows promise in clinical trial

Cell Therapy Slows Upper Limb Decline in Duchenne Muscular Dystrophy

Investigational deramiocel is back under FDA review again

Real-World Registry Study Shows Alzheimer's Drug Safety Outcomes

No new signals for lecanemab emerged in ALZ-NET

Recommended News For You

Low-Dose Radiation Provides Almost Perfect Control Over Slow-Growing Lymphoma.

Review looks at potential treatment targets in the tumor microenvironment.

MCh in Gynecologic Oncology: Admission, Medical School, Fees, Qualifications Information

Subcutaneous Cancer Immunotherapies Provide New Options for Physicians and Patients

Breast Cancer Patients Living Longer Post-Medicaid Expansion

Optimizing Sequencing of BCMA-Directed Therapies in Myeloma

Telemedicine Not Reaching Rural Psychiatric Patients

Recommended Articles For You

The benefits of using magnesium sulfate during pregnancy  

Revolutionizing Cancer Treatment: How Adoptive Cell Therapy is Overcoming Tumor Immune Evasion 

Glycopyrrolate: The Secret Weapon for Excessive Sweating  

Unraveling the Genetic Mystery of Hereditary Spherocytosis 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

PET-CT finds further-reaching metastases in patients with locally advanced breast cancer.

2.

Reasons Behind Refusing Stem Cell Transplantation in Certain Myeloma Patients.

3.

Hospitalization and mortality rates are associated with exposure to the omicron variant of COVID-19 in patients with solid cancer.

4.

AI System Beats Radiologists in Detecting Clinically Significant Prostate Cancer

5.

In heavily pretreated DLBCL, Triplet Scores a Survival Victory.

1.

The Precision Revolution: Bispecific Antibodies and Antibody-Drug Conjugates Reshaping the Oncology Landscape

2.

Is AI The New Radiologist For Breast MRI?

3.

Uncovering New Hope for Follicular Lymphoma Patients

4.

The Silent Signs: Uncovering Stomach Cancer Symptoms Before It's Too Late

5.

Unveiling the Chadwick Sign: A Revolutionary New Tool for Detecting Early Signs of Cancer

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

CDK4/6 Inhibitors Redefining Treatment for HR+/HER2- aBC In Post-Menopausal Women- A Panel Discussion

2.

Efficient Management of First line ALK-rearranged NSCLC - Part V

3.

Redefining Treatment Pathways in Relapsed/Refractory Adult B-Cell ALL

4.

Updates on Standard V/S High Risk Myeloma Treatment- The Next Part

5.

Current Cancer Scenario in India- Importance of Genomic Testing & Advancement in Diagnosis and Treatment

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot